Physician profile
Robert E Lane
NPI 1023001500
$9,477.03
in general payments reported to CMS, 2019-2025
45 companies · $805 in 2025
The $805 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,347 · 2020: $1,253 · 2021: $1,586 · 2022: $1,618 · 2023: $1,787 · 2024: $1,083 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,643 · Education: $31.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.97 |
| Education | $31.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,476.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,213.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $918.52 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $685.80 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $660.92 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $623.95 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $573.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $513.36 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Grifols USA, LLC | $352.73 | 2019-2024 | Prolastin-C Liquid |
| Astellas Pharma US INC | $336.51 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $294.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $255.05 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $183.19 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $108.79 | 2021-2023 | |
| Cranial Technologies, INC | $88.82 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.